Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06721351Not ApplicableActive Not Recruiting

Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

Role: collaborator

NCT04984200Completed

Assessment of EyeArt Performance With Retinal Cameras

Role: lead

NCT04567745Phase 1Completed

Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers

Role: collaborator

NCT04302012Completed

Assessment of EyeArt Performance With Retinal Imaging Devices

Role: lead

NCT03078231Completed

Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Role: lead

NCT03112005Completed

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

Role: lead

All 6 trials loaded